My humble 2 cents would be to sell the other half too. Praveen pointed out that Teva might be vulnerable to Elan's Tysabri upon it's return, now 2 months away, and I think he's right.
"....on the biotech battle-field, you need some élan...."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.